Premium
Calidi Biotherapeutics Inc (CLDI)
AMEX
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s...
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic...
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.18 | -8.49056603774 | 2.12 | 2.2 | 1.87 | 1111835 | 2.06630131 | CS |
| 4 | 0.27 | 16.1676646707 | 1.67 | 3.89 | 1.48 | 3105739 | 2.62350361 | CS |
| 12 | 0.75 | 63.025210084 | 1.19 | 3.89 | 0.73 | 1491422 | 2.17281299 | CS |
| 26 | -0.46 | -19.1666666667 | 2.4 | 3.89 | 0.73 | 1249685 | 2.07840143 | CS |
| 52 | -19.76 | -91.0599078341 | 21.7 | 24 | 0.73 | 1007627 | 2.81474864 | CS |
| 156 | -43.16 | -95.6984478936 | 45.1 | 50 | 0.73 | 818637 | 3.16031797 | CS |
| 260 | -43.16 | -95.6984478936 | 45.1 | 50 | 0.73 | 818637 | 3.16031797 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| MSTZT Rex 2X Inverse MSTR Daily Target ETF | US$ 1,0999 (15,44%) | 408,55M |
| FXIiShares China Large Cap | US$ 33,30 (8,22%) | 153,24M |
| KWEBKraneShares CSI China Internet | US$ 34,21 (10,04%) | 55,9M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 29,23 (-1,28%) | 54,97M |
| NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3,32 (4,90%) | 45,75M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
